1. Home
  2. ALLO vs HZO Comparison

ALLO vs HZO Comparison

Compare ALLO & HZO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • HZO
  • Stock Information
  • Founded
  • ALLO 2017
  • HZO 1998
  • Country
  • ALLO United States
  • HZO United States
  • Employees
  • ALLO N/A
  • HZO N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • HZO Auto & Home Supply Stores
  • Sector
  • ALLO Health Care
  • HZO Consumer Discretionary
  • Exchange
  • ALLO Nasdaq
  • HZO Nasdaq
  • Market Cap
  • ALLO 677.5M
  • HZO 787.2M
  • IPO Year
  • ALLO 2018
  • HZO 1998
  • Fundamental
  • Price
  • ALLO $2.27
  • HZO $29.31
  • Analyst Decision
  • ALLO Buy
  • HZO Strong Buy
  • Analyst Count
  • ALLO 12
  • HZO 6
  • Target Price
  • ALLO $10.06
  • HZO $42.67
  • AVG Volume (30 Days)
  • ALLO 2.6M
  • HZO 240.5K
  • Earning Date
  • ALLO 11-07-2024
  • HZO 10-31-2024
  • Dividend Yield
  • ALLO N/A
  • HZO N/A
  • EPS Growth
  • ALLO N/A
  • HZO N/A
  • EPS
  • ALLO N/A
  • HZO 1.65
  • Revenue
  • ALLO $43,000.00
  • HZO $2,431,008,000.00
  • Revenue This Year
  • ALLO N/A
  • HZO $1.93
  • Revenue Next Year
  • ALLO $5,902.96
  • HZO $4.96
  • P/E Ratio
  • ALLO N/A
  • HZO $17.81
  • Revenue Growth
  • ALLO 26.47
  • HZO 1.52
  • 52 Week Low
  • ALLO $2.01
  • HZO $22.51
  • 52 Week High
  • ALLO $5.78
  • HZO $39.85
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 36.00
  • HZO 41.92
  • Support Level
  • ALLO $2.95
  • HZO $30.47
  • Resistance Level
  • ALLO $3.36
  • HZO $33.69
  • Average True Range (ATR)
  • ALLO 0.26
  • HZO 1.38
  • MACD
  • ALLO -0.06
  • HZO 0.01
  • Stochastic Oscillator
  • ALLO 0.91
  • HZO 19.27

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About HZO MarineMax Inc. (FL)

MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S.

Share on Social Networks: